These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15934878)

  • 1. Current and future pharmacological intervention for diabetic retinopathy.
    Comer GM; Ciulla TA
    Expert Opin Emerg Drugs; 2005 May; 10(2):441-55. PubMed ID: 15934878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in biochemical mechanisms of diabetic retinopathy.
    Giusti C; Gargiulo P
    Eur Rev Med Pharmacol Sci; 2007; 11(3):155-63. PubMed ID: 17970231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating diabetic retinopathy by tackling growth factor pathways.
    Chiarelli F; Giannini C; Di Marzio D; Mohn A
    Curr Opin Investig Drugs; 2005 Apr; 6(4):395-409. PubMed ID: 15898347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current approaches and perspectives in the medical treatment of diabetic retinopathy.
    Porta M; Allione A
    Pharmacol Ther; 2004 Aug; 103(2):167-77. PubMed ID: 15369682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacotherapy for diabetic retinopathy.
    Comer GM; Ciulla TA
    Curr Opin Ophthalmol; 2004 Dec; 15(6):508-18. PubMed ID: 15523197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological treatment of diabetic retinopathy.
    Lang GE
    Ophthalmologica; 2007; 221(2):112-7. PubMed ID: 17380065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic possibilities for diabetic macular oedema].
    Wiemer NG; Polak BC; Veckeneer MA
    Ned Tijdschr Geneeskd; 2006 Oct; 150(40):2183-7. PubMed ID: 17061428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy.
    Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
    Med Hypotheses; 2006; 66(5):1019-21. PubMed ID: 16188392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of protein kinase C might be harmful to diabetic retinopathy.
    Yamagishi S; Takeuchi M
    Med Hypotheses; 2004; 63(1):135-7. PubMed ID: 15193366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetic microangiopathy: physiopathological, clinical and therapeutic aspects.
    Camera A; Hopps E; Caimi G
    Minerva Endocrinol; 2007 Sep; 32(3):209-29. PubMed ID: 17912158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Medical treatment in diabetic retinopathy].
    Brănişteanu D; Graur M
    Rev Med Chir Soc Med Nat Iasi; 2005; 109(2):230-5. PubMed ID: 16607776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Changes of plasma endothelin-1 and vascular endothelial growth factor in diabetic retinopathy and the clinical application value thereof].
    Zhu H; Shi CH
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(40):2837-9. PubMed ID: 18167288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Outlook for the future in the treatment of diabetic retinopathy].
    Vialettes B; Silvestre-Aillaud P; Atlan-Gepner C
    Diabete Metab; 1994; 20(2 Pt 2):229-34. PubMed ID: 7528151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetic retinopathy: current management and experimental therapeutic targets.
    Ali TK; El-Remessy AB
    Pharmacotherapy; 2009 Feb; 29(2):182-92. PubMed ID: 19170588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing paradigms in the treatment of diabetic retinopathy.
    El-Asrar AM; Al-Mezaine HS; Ola MS
    Curr Opin Ophthalmol; 2009 Nov; 20(6):532-8. PubMed ID: 19644368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New prospects in the treatment of diabetic retinopathy. Current situation and pharmacological developments].
    Lagrèze WA
    MMW Fortschr Med; 2003 Apr; 145(14):37-8. PubMed ID: 15072277
    [No Abstract]   [Full Text] [Related]  

  • 18. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles.
    Patel JI; Tombran-Tink J; Hykin PG; Gregor ZJ; Cree IA
    Exp Eye Res; 2006 May; 82(5):798-806. PubMed ID: 16324700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of proliferative diabetic retinopathy.
    Gündüz K; Bakri SJ
    Compr Ophthalmol Update; 2007; 8(5):245-56. PubMed ID: 18201511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects for angiotensin receptor blockers in diabetic retinopathy.
    Sjølie AK
    Diabetes Res Clin Pract; 2007 May; 76 Suppl 1():S31-9. PubMed ID: 17321627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.